John Oyler - BeiGene Ex CoFounder
| B1GN34 Stock | BRL 42.30 1.46 3.34% |
Insider
John Oyler is Ex CoFounder of BeiGene
| Age | 55 |
| Phone | 781-801-1800 |
| Web | https://www.beigene.com |
John Oyler Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Oyler against BeiGene stock is an integral part of due diligence when investing in BeiGene. John Oyler insider activity provides valuable insight into whether BeiGene is net buyers or sellers over its current business cycle. Note, BeiGene insiders must abide by specific rules, including filing SEC forms every time they buy or sell BeiGene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Oyler over two months ago Disposition of 428 shares by John Oyler of BeiGene at 234.2728 subject to Rule 16b-3 | ||
John Oyler over two months ago Disposition of 1452 shares by John Oyler of BeiGene at 236.3695 subject to Rule 16b-3 | ||
John Oyler over six months ago Disposition of tradable shares by John Oyler of BeiGene at 150.85 subject to Rule 16b-3 | ||
John Oyler over six months ago Disposition of 7924 shares by John Oyler of BeiGene at 154.2084 subject to Rule 16b-3 |
BeiGene Management Efficiency
The company has return on total asset (ROA) of (0.1971) % which means that it has lost $0.1971 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5254) %, meaning that it generated substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Melissa Moore | Moderna | N/A | |
| Jens Holstein | BIONTECH SE DRN | 60 | |
| William Young | Vertex Pharmaceuticals Incorpor | 74 | |
| Diana McKenzie | Vertex Pharmaceuticals Incorpor | 54 | |
| Michael Parini | Vertex Pharmaceuticals Incorpor | 43 | |
| David Altshuler | Vertex Pharmaceuticals Incorpor | 53 | |
| Kristen Ambrose | Vertex Pharmaceuticals Incorpor | 46 | |
| Sangeeta Bhatia | Vertex Pharmaceuticals Incorpor | 50 | |
| Heraldo Marchezini | Biomm SA | N/A | |
| Paul Silva | Vertex Pharmaceuticals Incorpor | 51 | |
| Margaret McGlynn | Vertex Pharmaceuticals Incorpor | 59 | |
| James Mock | Moderna | 46 | |
| Jens Okkels | Ascendis Pharma AS | 62 | |
| Yuchun Lee | Vertex Pharmaceuticals Incorpor | 52 | |
| Michael Boehler | BIONTECH SE DRN | N/A | |
| Peter Rasmussen | Ascendis Pharma AS | 54 | |
| Damian Esq | Vertex Pharmaceuticals Incorpor | 47 | |
| Ryan Richardson | BIONTECH SE DRN | 44 | |
| Jeffrey MD | Vertex Pharmaceuticals Incorpor | 67 | |
| Lavina CFA | Moderna | N/A | |
| Kennett Sprogoe | Ascendis Pharma AS | 44 | |
Management Performance
| Return On Equity | -0.53 | |||
| Return On Asset | -0.2 |
BeiGene Leadership Team
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Oyler, Ex CoFounder | ||
| Xiaodong Wang, Chairman CoFounder | ||
| Mi Zhou, Director Relations | ||
| Daniel Maller, VP Accounting | ||
| Chan Lee, G Counsel | ||
| Wang Lai, Global RD | ||
| Kevin Mannix, VP Relations | ||
| Diana Francis, VP Compliance | ||
| Julia Wang, CFO Officer | ||
| Xiaobin Wu, COO Pres |
BeiGene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.53 | |||
| Return On Asset | -0.2 | |||
| Profit Margin | (1.68) % | |||
| Operating Margin | (1.52) % | |||
| Current Valuation | 93.43 B | |||
| Shares Outstanding | 1.35 B | |||
| Price To Book | 2.09 X | |||
| Price To Sales | 92.86 X | |||
| Revenue | 1.18 B | |||
| Gross Profit | (447.86 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in BeiGene Stock
When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.